Clinical trials: pills and oral medicines
Clostridium Difficile Infection Recurrence
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
The objective is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with vancomycin for cure of recurrent C.
- Trial name
- NCT03617445
- Testing
- FMT oral capsule, Oral Vancomycin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Stimulant Use
Drugs Brain and Behavior (DDP)
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
- Trial name
- DDP (NCT04642820)
- Testing
- Methamphetamine
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Barotrauma;Ear
Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning.
- Trial name
- NCT04332211
- Testing
- Hyperbaric Oxygen Therapy, Pseudoephedrine 60 MG
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Maryland, Baltimore
Harm Reduction, HIV Infections
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.
- Conditions
- Harm Reduction, HIV Infections, Drug Use
- Trial name
- NCT04650269
- Testing
- Biktarvy 50Mg-200Mg-25Mg Tablet, HIV care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Miami
Alcohol Use Disorder
N-Acetylcysteine for Adolescent Alcohol Use Disorder
This is a 8-week randomized, placebo-controlled trial testing the effects of N-acetylcysteine (NAC), on a platform of weekly evidence-based brief alcohol intervention for 120 adolescents with alcohol use disorder (AUD).
- Trial name
- NCT03707951
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Medical University of South Carolina
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Drug-Drug Interaction, Heathy Volunteer
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Primary objective: 1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam. 2.
- Trial name
- NCT05492318
- Testing
- Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution
- Where
- Portugal
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
COVID-19
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
- Trial name
- SAIVE (NCT05305560)
- Testing
- Ivermectin Tablets
- Where
- Bulgaria
- Volunteers
- 400 people
- Sponsor
- MedinCell S.A
Atrial Fibrillation, Atrial Flutter
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health…
- Trial name
- NCT05391893
- Testing
- Oral, Intravenous drug
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- Corewell Health South
Neuromyelitis Optica Spectrum Disorder
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of…
- Trial name
- NCT04660539
- Testing
- satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF)
- Where
- 53 sites in United States, Bulgaria and 16 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Cystinosis
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate immediate release) which must be taken every…
- Trial name
- NCT01197378
- Testing
- Cysteamine Bitartrate Delayed-release Capsules
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Hiv
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls
- Trial name
- DUALING (NCT04707326)
- Testing
- Dolutegravir / Lamivudine Pill
- Where
- 9 sites in Netherlands
- Volunteers
- 2,040 people
- Sponsor
- Erasmus Medical Center
Metabolic Acidosis, Chronic Kidney Disease
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
This is a pilot, randomized, double-blinded, placebo-controlled, 12-month trial of 50 patients with CKD stage 3b-4 with metabolic acidosis to examine the effect of sodium bicarbonate therapy on cognitive and cerebrovascular…
- Conditions
- Metabolic Acidosis, Chronic Kidney Disease, Cognitive Dysfunction
- Trial name
- NCT04600323
- Testing
- Sodium Bicarbonate Tablets
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Colorado, Denver
Cystinosis
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the…
- Trial name
- NCT01000961
- Testing
- Cystagon® (Cysteamine Bitartrate), Cysteamine Bitartrate Delayed-release Capsules (RP103)
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Amgen
Mitochondrial Diseases
Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
The purpose of this study is to test how different doses of a statin, Lipitor, affect muscle health and function, and cardiovascular fitness.
- Trial name
- NCT03351998
- Testing
- Lipitor 20Mg Tablet, Lipitor 80Mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cannabis Use Disorder
N-Acetylcysteine for Youth Cannabis Use Disorder
This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO, yielding two equally-allocated treatment…
- Trial name
- NCT03055377
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Medical University of South Carolina
Healthy
Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)
This study aims to demonstrate the bioequivalence between the formulation of 5 mg/mL Tramadol Hydrochloride Oral Solution (08P1902F0) Relative to the reference product Contramal® (100 mg/mL Oral Solution).
- Trial name
- NCT05716763
- Testing
- Tramadol Hydrochloride 5 MG/ML Oral Solution, Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))
- Where
- Jordan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unither Pharmaceuticals, France
Erosive Osteoarthritis
The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect)…
- Trial name
- NCT04403698
- Testing
- Alendronate Effervescent Oral Tablet
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.